Skip to Main Content

Author Details

Matthias Fischer
University Children's Hospital of Cologne
2003
149
50
PMIDPaper TitleJournal TitlePublished Year
35899825Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma.Cancer Rep (Hoboken)2023
35899825Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma.Cancer Rep (Hoboken)2023
37606995Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.J Clin Invest2023
36882421SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry.Nat Commun2023
36807339Genomic ALK alterations in primary and relapsed neuroblastoma.Br J Cancer2023
37435859LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.EMBO Mol Med2023
37606995Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.J Clin Invest2023
37435859LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.EMBO Mol Med2023
36882421SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry.Nat Commun2023
36807339Genomic ALK alterations in primary and relapsed neuroblastoma.Br J Cancer2023
36153564Reliable assessment of telomere maintenance mechanisms in neuroblastoma.Cell Biosci2022
35953764Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.Cell Oncol (Dordr)2022
36153564Reliable assessment of telomere maintenance mechanisms in neuroblastoma.Cell Biosci2022
35689207Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.Mol Cancer2022
35490242The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.J Exp Clin Cancer Res2022
35484422MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.Nat Cancer2022
35857500RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.Sci Adv2022
35857500RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.Sci Adv2022
35490242The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.J Exp Clin Cancer Res2022
35689207Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.Mol Cancer2022
35484422MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.Nat Cancer2022
35953764Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.Cell Oncol (Dordr)2022
33310889Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.Clin Cancer Res2021
34016720Druggable epigenetic suppression of interferon-induced chemokine expression linked to <i>MYCN</i> amplification in neuroblastoma.J Immunother Cancer2021
33627664Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.Nat Commun2021
34050933A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development.Clin Pharmacol Ther2021
33826231Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification.Pediatr Blood Cancer2021
33718189<i>MYCN</i> Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma.Front Oncol2021
33372039Subcellular Distribution of p53 by the p53-Responsive lncRNA <i>NBAT1</i> Determines Chemotherapeutic Response in Neuroblastoma.Cancer Res2021
33310889Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.Clin Cancer Res2021
34789871Reporting guidelines for human microbiome research: the STORMS checklist.Nat Med2021
34503173Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by <i>MYCN</i> Amplification.Cancers (Basel)2021
34782764Chromothripsis followed by circular recombination drives oncogene amplification in human cancer.Nat Genet2021
34442335Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.J Pers Med2021
34780709Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.Lancet Oncol2021
34373263The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.Cancer Discov2021
34815394Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.Nat Commun2021
33718189<i>MYCN</i> Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma.Front Oncol2021
33627664Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.Nat Commun2021
33826231Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification.Pediatr Blood Cancer2021
34442335Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.J Pers Med2021
34789871Reporting guidelines for human microbiome research: the STORMS checklist.Nat Med2021
34815394Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.Nat Commun2021
34782764Chromothripsis followed by circular recombination drives oncogene amplification in human cancer.Nat Genet2021
34780709Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.Lancet Oncol2021
34503173Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by <i>MYCN</i> Amplification.Cancers (Basel)2021
34016720Druggable epigenetic suppression of interferon-induced chemokine expression linked to <i>MYCN</i> amplification in neuroblastoma.J Immunother Cancer2021
34050933A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development.Clin Pharmacol Ther2021
34373263The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.Cancer Discov2021
33372039Subcellular Distribution of p53 by the p53-Responsive lncRNA <i>NBAT1</i> Determines Chemotherapeutic Response in Neuroblastoma.Cancer Res2021
  • 1 - 50 of 298

Recommended Authors

Komal S Rathi
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2014
Number of shared co-authors 7
Jaime M Guidry Auvil
National Cancer Institute
Career Start Year 2013
Number of shared co-authors 11
Nicolle Diessl
German Cancer Research Center (DKFZ)
Career Start Year 2010
Number of shared co-authors 18
David J H Shih
University of Texas MD Anderson Cancer Center Houston
Career Start Year 2009
Number of shared co-authors 22
Adrian M Dubuc
Dana-Farber Cancer Institute
Career Start Year 2008
Number of shared co-authors 16
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 5
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 13
Marc Remke
and Clinical Immunology, Heinrich Heine University, University Hospital Dusseldorf
Career Start Year 2007
Number of shared co-authors 31
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 24
Roel G W Verhaak
Yale School of Medicine
Career Start Year 2004
Number of shared co-authors 16
Daniel Martinez
Perelman School of Medicine at the University of Pennsylvania
Career Start Year 2002
Number of shared co-authors 4
Yael P Mosse
Perelman School of Medicine at the University of Pennsylvania
Career Start Year 2002
Number of shared co-authors 14
Sharon J Diskin
Children's Hospital of Philadelphia
Career Start Year 2002
Number of shared co-authors 17
Patrick G Buckley
Beaumont Hospital
Career Start Year 2002
Number of shared co-authors 2
Sven Bilke
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 2
Ga??lle Pierron
Institut Curie Hospital
Career Start Year 2001
Number of shared co-authors 19
Xiang Chen
St. Jude Children's Research Hospital
Career Start Year 1999
Number of shared co-authors 5
Qing-Rong Chen
Center for Biomedical Informatics and Information Technology
Career Start Year 1996
Number of shared co-authors 11
Steven C Clifford
Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer
Career Start Year 1994
Number of shared co-authors 23
Kristina A Cole
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1994
Number of shared co-authors 7
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 9
Marcel Kool
Hopp Children's Cancer Center (KiTZ)
Career Start Year 1990
Number of shared co-authors 35
Dirk Geerts
Amsterdam University Medical Center
Career Start Year 1989
Number of shared co-authors 1
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 13
Antonio Iavarone
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Career Start Year 1989
Number of shared co-authors 15
Poul H Sorensen
British Columbia Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 18
William A Weiss
University of California san francisco
Career Start Year 1985
Number of shared co-authors 26
Anna Lasorella
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Career Start Year 1984
Number of shared co-authors 5
Ching C Lau
Baylor College of Medicine
Career Start Year 1982
Number of shared co-authors 9
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 15

Collaborators

Frank Berthold
Co-authored papers 47
Frank Westermann
Co-authored papers 42
André Oberthuer
Co-authored papers 37
Johannes H Schulte
Co-authored papers 33
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 26
Angelika Eggert
Co-authored papers 26
Yvonne Kahlert
Co-authored papers 23
Jo Vandesompele
Co-authored papers 17
Olaf Witt
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 12
Roland Eils
Berlin Institute of Health (BIH) and Charite
Co-authored papers 11
Ming Shi
Co-authored papers 10
Gudrun Schleiermacher
Institut Curie
Co-authored papers 8
Glenn M Marshall
Children's Cancer Institute, Lowy Cancer Research Centre
Co-authored papers 8
Pieter Mestdagh
Co-authored papers 8
Anton G Henssen
Co-authored papers 7
Michelle Haber
School of Clinical Medicine
Co-authored papers 7
Dilafruz Juraeva
Co-authored papers 7
Weida Tong
National Center for Toxicological Research
Co-authored papers 6
Jan Koster
Amsterdam University Medical Centers location AMC
Co-authored papers 6
Peter F Ambros
Children's Cancer Research Institute, Medical University of Vienna
Co-authored papers 6
Jan J Molenaar
Co-authored papers 6
John M Maris
Children's Hospital of Philadelphia
Co-authored papers 5
Michael D Hogarty
Co-authored papers 5
Andreas E Kulozik
Co-authored papers 5
Elias Rodriguez-Fos
Co-authored papers 5
Andreas von Deimling
Co-authored papers 5
Stefan M Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 5
Russell D Wolfinger
SAS Institute
Co-authored papers 5
Marc Zapatka
Co-authored papers 5
Till Milde
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 5
Release 1.2